Get the Stockscreener App
1.02
0.49%
0.005
After Hours:
1.02
Okyo Pharma Limited stock is traded at $1.02, with a volume of 25,404.
It is up +0.49% in the last 24 hours and down -15.00% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.015
Open:
$1
24h Volume:
25,404
Relative Volume:
0.14
Market Cap:
$33.84M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-6.2195
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+0.99%
1M Performance:
-15.00%
6M Performance:
-31.54%
1Y Performance:
-44.86%
1-Day Range:
$1.00
$1.04
1-Week Range:
$0.98
$1.04
52-Week Range:
$0.8075
$2.95
Okyo Pharma Limited Stock (OKYO) Company Profile
Okyo Pharma Limited Stock (OKYO) Latest News
Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News
Understanding OKLO’s book value per share for better investment insights - US Post News
XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Ok Play's board approves allotment of Equity sharesCheck details - India.com
Oklo Inc. (NYSE:OKLO) Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share - MarketBeat
Oklo Inc. (NYSE:OKLO) Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share - Defense World
XTX Topco Ltd Acquires Shares of 33,954 Omega Healthcare Investors, Inc. (NYSE:OHI) - Defense World
Traders Buy High Volume of Oklo Call Options (NYSE:OKLO) - MarketBeat
Orkla India eyes public listing after completing restructuring | Company Business News - Mint
Tomohiro Okada named president, director of Universal Ent - GGRAsia
Multibagger Penny Stock Under Rs 20 Surges Over 50 Per Cent From Its 52-Week Low; Board Allots Equity Shares On Conversion Of Warrants To Promoters - Dalal Street Investment Journal
OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World
Oklo Inc. (OKLO) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
OKYO Pharma executive chairman increases stake - Investing.com
OKYO Pharma executive increases stake in company By Investing.com - Investing.com Australia
OKYO Pharma executive chairman increases stake By Investing.com - Investing.com UK
OKYO Pharma executive increases stake in company - Investing.com
OKYO Pharma executive increases stake in company By Investing.com - Investing.com Canada
OKYO Pharma Chairman Boosts Stake, Advances Trials - TipRanks
Okyo Pharma announces acquisition of shares by chairman - TipRanks
OKYO Pharma Announces Chairman Acquires Shares - GlobeNewswire
OKYO Pharma chair increases shareholdings - Proactive Investors UK
OKYO Pharma Announces Chairman Acquires Shares - Yahoo Finance UK
OKYO Pharma Announces Chairman Acquires Shares - Informazione.it
OKYO Pharma executive increases stake - Investing.com
OKYO Pharma Ltd expected to post a loss of 11 cents a shareEarnings Preview - XM
OKYO Pharma executive increases stake By Investing.com - Investing.com Canada
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease - Yahoo Finance UK
OKYO Pharma executive increases stake - Investing.com India
OKYO Pharma executive increases stake By Investing.com - Investing.com UK
OKYO Pharma executive increases stake in company By Investing.com - Investing.com UK
OKYO Pharma (NASDAQ:OKYO) & Moderna (NASDAQ:MRNA) Financial Analysis - Defense World
OKYO Pharma stock poised for potential gains ahead of Phase 2b dataH.C. Wainwright - Investing.com
OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright - Defense World
OKYO Pharma (LON:OKYO) Trading Down 24.3% - Defense World
OKYO Pharma secures US patent for dry eye disease therapy - Investing.com
OKYO Pharma secures key US patent for dry eye disease treatment - Investing.com
OKYO Pharma Secures U.S. Patent for DED Therapy - TipRanks
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease - GlobeNewswire
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease - StockTitan
OKYO Pharma secures key US patent for dry eye disease therapy - Proactive Investors UK
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease - Yahoo Finance
OKYO Pharma Exec Chairman Increases Stake - Investing.com India
The Significance of Moving Averages in OKYO Pharma Limited Inc. (OKYO) Price Performance - The InvestChronicle
OKYO Pharma Exec Chairman Increases Stake By Investing.com - Investing.com Canada
OKYO Pharma Exec Chairman Increases Stake By Investing.com - Investing.com Australia
OKYO Pharma CEO Interview to Air on Bloomberg TV - Yahoo Finance UK
OKYO Pharma Advances in Ocular Disease Therapies - TipRanks
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
OKYO Pharma CEO Interview to Air on Bloomberg TV - GlobeNewswire
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):